Janssen-sponsored congress materials from select Neuroscience Conferences:

• ACTRIMS 2021 (February 24-26, 2021)
• Psych Congress 2020 (September 10-13, 2020)
• MSVirtual 2020 (September 11-13, 2020)

 

Data presented at ACTRIMS 2021

Virtual congress materials from ACTRIMS congress can be accessed directly at https://www.abstractsonline.com/pp8/#!/9245.

Abstracts

• Assessing the Impact of Disease Activity and Fatigue Symptom on Work Productivity and Activity Impairment in Patients with Relapsing Multiple Sclerosis
• Changes in Fatigue Status on the FSIQ-RMS Symptoms Domain in the Phase 3 OPTIMUM Study
• Evaluating the Impact of Fatigue Symptoms on Work Productivity and Activity Impairment using Longitudinal Data from the Phase III OPTIMUM study
• MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity
• Measuring the symptoms and impacts of fatigue in adults with relapsing multiple sclerosis using a novel disease specific scale: A real-world study in US population
• The Humanistic Burden Associated with Fatigue in Relapsing-remitting Multiple Sclerosis.
• The Economic Burden Associated with Fatigue in Relapsing-remitting Multiple Sclerosis
• A Central Effect of Ponesimod on Neuroinflammation in a Pre-Clinical Model of Multiple Sclerosis
• Identifying and Characterizing Fatigue in Patients Diagnosed with Multiple Sclerosis on Disease-Modifying Therapies Using Real World Evidence

 

Data presented at Psych Congress 2020

Virtual congress materials from Psych Congress can be accessed directly at https://www.psychcongress.com/posters.

Posters:

• Evaluation of Treatment Failure in a 20-month Randomized, Open-Label Study of Paliperidone Palmitate Versus Oral Antipsychotics in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder
• Evaluation of Major Treatment Failures from the Disease Recovery Evaluation and Modification (DREaM) Study
• A Systematic Literature Review of Schizophrenia Clinical Practice Guidelines: Recommendations on use of Long-acting Injectable Antipsychotic Medications
• Hospitalizations, Emergency Room Visits and Adherence Among Patients With Schizophrenia Initiated on Long-Acting Injectable Versus Oral Antipsychotics: A Systematic Review and Meta-Analysis
• Medication Adherence, Healthcare Resource Utilization, and Costs among Medicaid Beneficiaries with Schizophrenia Treated with Once-monthly Paliperidone Palmitate or Once-every-three-months Paliperidone Palmitate
• Drivers of Prescribing Long-Acting Injectable Antipsychotics to Patients with Schizophrenia
• Characteristics of young adults with schizophrenia using Colorado’s All Payer Claims Database (CO-APCD)
• Real world analysis of insurance churn among young adult patients with schizophrenia using the Colorado All Payer Claims Database (CO-APCD)
• The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System
• Antipsychotic Treatment Utilization and Healthcare Spending in Medicaid Beneficiaries by States and Regions Within the United States
• Non-Healthcare Societal Burden of Schizophrenia Among Veterans
• Characteristics of Commercially Insured Patients Initiated on Esketamine Nasal Spray in a Real-World Setting
• Prevalence of Pre-existing Conditions for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies among Patients with Treatment-Resistant Depression
• Budget impact analysis of Esketamine Nasal Spray in a sub-population of adults with major depressive disorder and high unmet need: payer perspective in the United States
• Cluster Analysis of Care Pathways in Major Depressive Disorder with Suicidal Ideation or Probable Suicide Attempt
• Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder Having Active Suicidal Ideation with Intent: Pooled Randomized, Controlled Trials

 

Data presented at MSVirtual 2020

Virtual congress materials from MSVirtual congress can be accessed directly at https://library.msvirtual2020.org/virtual-library-search?product_id=7.

Posters

• Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: Phase 3 OPTIMUM study – P0071
• Effect on disability measures and MSFC in patients with relapsing multiple sclerosis from the phase 3 ponesimod versus teriflunomide optimum study – P0204
• Cardiac Safety of Ponesimod in Relapsing Multiple Sclerosis in the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study -P0194
• Establishing Meaningful Change Threshold in Multiple Sclerosis related Fatigue on Fatigue Symptoms & Impacts Questionnaire-Relapsing MS (FSIQ-RMS) – P1027
• Long-term efficacy and safety of ponesimod: Results from randomized phase II core and extension studies in relapsing remitting multiple sclerosis – P0215
• Treatment Persistency for Patients in a Phase 2 Long-Term Extension Study of Ponesimod – P0177
• Pharmacokinetic-Pharmacodynamic Models of Lymphocyte Count and Heart Rate Following Ponesimod Dosing in a Phase 2 Study in Multiple Sclerosis Patients – P0224
• A real-world study characterizing symptoms and impacts of fatigue in US adults with relapsing multiple sclerosis using a novel disease specific scale – P1004
• Comorbidity and Economic Burdens of Fatigue Among Patients with Relapsing-Remitting Multiple Sclerosis in the United States – P0857
• Treatment Preferences of Patients with Relapsing Multiple Sclerosis: A Discrete Choice Experiment – P1064
• Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Model-Based Meta-Analysis for Annual Relapse Rate – P0049
• Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Longitudinal Model-Based Meta-Analysis for Confirmed Disability Accumulation – P0048
• Quality of life and economic burden of fatigue in people with multiple sclerosis: a systematic literature review – P1048